首页 > 最新文献

Bone Marrow Research最新文献

英文 中文
BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death. BET抑制抑制急性髓系白血病细胞中S100A8和S100A9的表达并与柔红霉素协同引起细胞死亡
Pub Date : 2018-05-31 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5742954
Helen J S Stewart, Sabah Chaudry, Asante Crichlow, Freya Luiling Feilding, Timothy J T Chevassut

S100A8 and S100A9 are both members of the S100 family and have been shown to play roles in myeloid differentiation, autophagy, apoptosis, and chemotherapy resistance. In this study we demonstrate that the BET-bromodomain inhibitor JQ1 causes rapid suppression of S100A8 and S100A9 mRNA and protein in a reversible manner. In addition, we show that JQ1 synergises with daunorubicin in causing AML cell death. Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9 protein levels in AML cell lines which is overcome by cotreatment with JQ1. This suggests that JQ1 synergises with daunorubicin in causing apoptosis via suppression of S100A8 and S100A9 levels.

S100A8和S100A9都是S100家族的成员,已被证明在髓细胞分化、自噬、凋亡和化疗耐药中发挥作用。在这项研究中,我们证明了β -溴域抑制剂JQ1以可逆的方式快速抑制S100A8和S100A9的mRNA和蛋白质。此外,我们发现JQ1与柔红霉素协同作用导致AML细胞死亡。单药柔红霉素可引起AML细胞系中S100A8和S100A9蛋白水平的剂量依赖性和时间依赖性增加,这可通过与JQ1共处理来克服。这表明JQ1通过抑制S100A8和S100A9水平与柔红霉素协同导致细胞凋亡。
{"title":"BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death.","authors":"Helen J S Stewart,&nbsp;Sabah Chaudry,&nbsp;Asante Crichlow,&nbsp;Freya Luiling Feilding,&nbsp;Timothy J T Chevassut","doi":"10.1155/2018/5742954","DOIUrl":"https://doi.org/10.1155/2018/5742954","url":null,"abstract":"<p><p>S100A8 and S100A9 are both members of the S100 family and have been shown to play roles in myeloid differentiation, autophagy, apoptosis, and chemotherapy resistance. In this study we demonstrate that the BET-bromodomain inhibitor JQ1 causes rapid suppression of <i>S100A8</i> and <i>S100A9</i> mRNA and protein in a reversible manner. In addition, we show that JQ1 synergises with daunorubicin in causing AML cell death. Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9 protein levels in AML cell lines which is overcome by cotreatment with JQ1. This suggests that JQ1 synergises with daunorubicin in causing apoptosis via suppression of S100A8 and S100A9 levels.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/5742954","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36269418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Antimicrobial-Induced Cytopenia and Bone Marrow Hypocellularity in Patients with Cirrhosis. 肝硬化患者抗菌剂诱导的细胞减少和骨髓细胞减少。
Pub Date : 2018-05-14 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4029648
Anupama Patil, Vikas Khillan, Monika Thakur, Pratibha Kale, Chhagan Bihari

There is great variation in cytopenias in cirrhotic patients with same severity and hypersplenism and their causative factors are not clear. Recent studies have highlighted the role of gut microbiome in regulation of constant and emergency hematopoiesis. Broad-spectrum antibiotics can disrupt the homeostatic or adaptive microbiota in cirrhosis, leading to impaired hematopoiesis and a higher susceptibility to infections. We studied all patients with cirrhosis with cytopenia (anemia, leucopenia, and/or thrombocytopenia), admitted in the Institute of Liver & Biliary Sciences, between January 2016 and July 2017, who underwent a bone marrow examination. The effect of the different antimicrobial agents on peripheral blood counts and bone marrow cellularity was assessed. A total of 196 patients' data was analyzed for this study. Patients on antimicrobials (n = 115) had significantly lower hemoglobin (p < 0.001), total leucocyte count (p = 0.048), and platelet count (p = 0.043) compared to patients not on antimicrobials. On unadjusted analysis, significant association with thrombocytopenia existed in beta-lactams (OR = 1.56, 95% CI = 1.06-2.40), quinolones (OR = 1.66, 95% CI = 1.11-2.61), and antifungals (OR = 2.24, 95% CI = 1.96-4.34). Cephalosporins were found to be significantly associated with anemia (OR = 1.91, 95% CI = 1.07-3.41). Patients who received antimicrobials had hypocellular marrow (p < 0.001) as compared to nonrecipients of antibiotics. The adjusted analysis showed that quinolones and beta-lactam antibiotics are the drug classes having significant association with thrombocytopenia and alternative class of drug should be explored in these patients to avoid severe thrombocytopenia.

相同严重程度的肝硬化患者和脾功能亢进患者的血小板减少有很大差异,其病因尚不清楚。最近的研究强调了肠道微生物组在持续和紧急造血中的调节作用。广谱抗生素可破坏肝硬化的内稳态或适应性微生物群,导致造血功能受损和对感染的易感性增加。我们研究了2016年1月至2017年7月期间在肝脏和胆道科学研究所接受骨髓检查的所有肝硬化伴细胞减少(贫血、白细胞减少和/或血小板减少)患者。评估不同抗菌药物对外周血计数和骨髓细胞的影响。本研究共分析了196例患者的数据。与未使用抗菌素的患者相比,使用抗菌素的患者(n = 115)的血红蛋白(p < 0.001)、总白细胞计数(p = 0.048)和血小板计数(p = 0.043)显著降低。在未经校正的分析中,β -内酰胺类药物(OR = 1.56, 95% CI = 1.06-2.40)、喹诺酮类药物(OR = 1.66, 95% CI = 1.11-2.61)和抗真菌药物(OR = 2.24, 95% CI = 1.96-4.34)与血小板减少症存在显著关联。头孢菌素与贫血显著相关(OR = 1.91, 95% CI = 1.07-3.41)。与未接受抗生素治疗的患者相比,接受抗菌素治疗的患者骨髓细胞减少(p < 0.001)。调整后的分析显示,喹诺酮类和β -内酰胺类抗生素是与血小板减少有显著相关性的药物类别,这类患者应探索替代药物类别,以避免严重的血小板减少。
{"title":"Antimicrobial-Induced Cytopenia and Bone Marrow Hypocellularity in Patients with Cirrhosis.","authors":"Anupama Patil,&nbsp;Vikas Khillan,&nbsp;Monika Thakur,&nbsp;Pratibha Kale,&nbsp;Chhagan Bihari","doi":"10.1155/2018/4029648","DOIUrl":"https://doi.org/10.1155/2018/4029648","url":null,"abstract":"<p><p>There is great variation in cytopenias in cirrhotic patients with same severity and hypersplenism and their causative factors are not clear. Recent studies have highlighted the role of gut microbiome in regulation of constant and emergency hematopoiesis. Broad-spectrum antibiotics can disrupt the homeostatic or adaptive microbiota in cirrhosis, leading to impaired hematopoiesis and a higher susceptibility to infections. We studied all patients with cirrhosis with cytopenia (anemia, leucopenia, and/or thrombocytopenia), admitted in the Institute of Liver & Biliary Sciences, between January 2016 and July 2017, who underwent a bone marrow examination. The effect of the different antimicrobial agents on peripheral blood counts and bone marrow cellularity was assessed. A total of 196 patients' data was analyzed for this study. Patients on antimicrobials (<i>n</i> = 115) had significantly lower hemoglobin (<i>p</i> < 0.001), total leucocyte count (<i>p</i> = 0.048), and platelet count (<i>p</i> = 0.043) compared to patients not on antimicrobials. On unadjusted analysis, significant association with thrombocytopenia existed in beta-lactams (OR = 1.56, 95% CI = 1.06-2.40), quinolones (OR = 1.66, 95% CI = 1.11-2.61), and antifungals (OR = 2.24, 95% CI = 1.96-4.34). Cephalosporins were found to be significantly associated with anemia (OR = 1.91, 95% CI = 1.07-3.41). Patients who received antimicrobials had hypocellular marrow (<i>p</i> < 0.001) as compared to nonrecipients of antibiotics. The adjusted analysis showed that quinolones and beta-lactam antibiotics are the drug classes having significant association with thrombocytopenia and alternative class of drug should be explored in these patients to avoid severe thrombocytopenia.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4029648","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36210391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Comparative Analysis of Cellular and Growth Factor Composition in Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma. 骨髓抽吸浓缩液和富血小板血浆中细胞和生长因子组成的比较分析。
Pub Date : 2018-02-25 eCollection Date: 2018-01-01 DOI: 10.1155/2018/1549826
Hisashi Sugaya, Tomokazu Yoshioka, Toshiki Kato, Yu Taniguchi, Hiroshi Kumagai, Kojiro Hyodo, Osamu Ohneda, Masashi Yamazaki, Hajime Mishima

The purpose of this study was to quantify the stem cell and growth factor (GF) contents in the bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP) prepared from whole blood using a protocol established in our laboratory. We examined 10 patients with osteonecrosis of the femoral head who were treated by autologous BMAC transplantation at our hospital between January 2015 and June 2015. We quantified CD34+ and CD31-CD45-CD90+CD105+ cells in BMAC and PRP by flow cytometry. Additionally, we measured various GFs, that is, basic fibroblast growth factor (b-FGF), platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), transforming growth factor-β1 (TGF-β1), and bone morphogenetic protein-2 (BMP-2) in BMAC and PRP using enzyme-linked immunosorbent assays and statistical analyses. CD34+ and CD31-45-90+105+ cells accounted for approximately 1.9% and 0.03% of cells in BMAC and no cells in PRP. The concentration of b-FGF was higher in BMAC than in PRP (P < 0.001), whereas no significant differences in the levels of PDGF-BB, VEGF, TGF-β1, and BMP-2 were observed between the two types of sample. BMAC had an average of 1.9% CD34+ and 0.03% CD31-45-90+105+ cells and higher levels of b-FGF than those of PRP.

本研究的目的是定量骨髓抽吸浓缩液(BMAC)和富血小板血浆(PRP)中干细胞和生长因子(GF)的含量,使用我们实验室建立的方案。我们分析了2015年1月至2015年6月在我院行自体BMAC移植治疗的10例股骨头坏死患者。我们用流式细胞术定量BMAC和PRP中CD34+和CD31-CD45-CD90+CD105+细胞。此外,我们使用酶联免疫吸附法和统计学分析测量了BMAC和PRP中的各种GFs,即碱性成纤维细胞生长因子(b-FGF)、血小板衍生生长因子- bb (PDGF-BB)、血管内皮生长因子(VEGF)、转化生长因子-β1 (TGF-β1)和骨形态发生蛋白-2 (BMP-2)。BMAC细胞中CD34+和CD31-45-90+105+细胞约占1.9%和0.03%,PRP细胞中无细胞。BMAC中b-FGF浓度高于PRP (P < 0.001),而PDGF-BB、VEGF、TGF-β1、BMP-2水平在两种样品之间无显著差异。BMAC的CD34+细胞平均为1.9%,CD31-45-90+105+细胞平均为0.03%,b-FGF水平高于PRP。
{"title":"Comparative Analysis of Cellular and Growth Factor Composition in Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma.","authors":"Hisashi Sugaya,&nbsp;Tomokazu Yoshioka,&nbsp;Toshiki Kato,&nbsp;Yu Taniguchi,&nbsp;Hiroshi Kumagai,&nbsp;Kojiro Hyodo,&nbsp;Osamu Ohneda,&nbsp;Masashi Yamazaki,&nbsp;Hajime Mishima","doi":"10.1155/2018/1549826","DOIUrl":"https://doi.org/10.1155/2018/1549826","url":null,"abstract":"<p><p>The purpose of this study was to quantify the stem cell and growth factor (GF) contents in the bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP) prepared from whole blood using a protocol established in our laboratory. We examined 10 patients with osteonecrosis of the femoral head who were treated by autologous BMAC transplantation at our hospital between January 2015 and June 2015. We quantified CD34+ and CD31-CD45-CD90+CD105+ cells in BMAC and PRP by flow cytometry. Additionally, we measured various GFs, that is, basic fibroblast growth factor (b-FGF), platelet-derived growth factor-BB (PDGF-BB), vascular endothelial growth factor (VEGF), transforming growth factor-<i>β</i>1 (TGF-<i>β</i>1), and bone morphogenetic protein-2 (BMP-2) in BMAC and PRP using enzyme-linked immunosorbent assays and statistical analyses. CD34+ and CD31-45-90+105+ cells accounted for approximately 1.9% and 0.03% of cells in BMAC and no cells in PRP. The concentration of b-FGF was higher in BMAC than in PRP (<i>P</i> < 0.001), whereas no significant differences in the levels of PDGF-BB, VEGF, TGF-<i>β</i>1, and BMP-2 were observed between the two types of sample. BMAC had an average of 1.9% CD34+ and 0.03% CD31-45-90+105+ cells and higher levels of b-FGF than those of PRP.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/1549826","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36034295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 31
Optimization of Ex Vivo Murine Bone Marrow Derived Immature Dendritic Cells: A Comparative Analysis of Flask Culture Method and Mouse CD11c Positive Selection Kit Method. 体外小鼠骨髓未成熟树突状细胞的优化:瓶培养法与小鼠CD11c阳性选择试剂盒法的比较分析。
Pub Date : 2018-02-22 eCollection Date: 2018-01-01 DOI: 10.1155/2018/3495086
Rahul Ashok Gosavi, Sukeshani Salwe, Sandeepan Mukherjee, Ritwik Dahake, Sweta Kothari, Vainav Patel, Abhay Chowdhary, Ranjana A Deshmukh

12-14 days of culturing of bone marrow (BM) cells containing various growth factors is widely used method for generating dendritic cells (DCs) from suspended cell population. Here we compared flask culture method and commercially available CD11c Positive Selection kit method. Immature BMDCs' purity of adherent as well as suspended cell population was generated in the decreasing concentration of recombinant-murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) in nontreated tissue culture flasks. The expression of CD11c, MHCII, CD40, and CD86 was measured by flow cytometry. We found significant difference (P < 0.05) between the two methods in the adherent cells population but no significant difference was observed between the suspended cell populations with respect to CD11c+ count. However, CD11c+ was significantly higher in both adhered and suspended cell population by culture method but kit method gave more CD11c+ from suspended cells population only. On the other hand, using both methods, immature DC expressed moderate level of MHC class II molecules as well as low levels of CD40 and CD86. Our findings suggest that widely used culture method gives the best results in terms of yield, viability, and purity of BMDCs from both adherent and suspended cell population whereas kit method works well for suspended cell population.

培养含有多种生长因子的骨髓细胞(BM) 12-14天是目前广泛采用的从悬浮细胞群中生成树突状细胞(DCs)的方法。我们比较了瓶培养法和市售CD11c阳性选择试剂盒法。在未处理的组织培养瓶中降低重组小鼠粒细胞-巨噬细胞集落刺激因子(rmGM-CSF)的浓度,可以提高未成熟bmdc的贴壁和悬浮细胞群的纯度。流式细胞术检测CD11c、MHCII、CD40、CD86的表达。我们发现两种方法在贴壁细胞群中有显著差异(P < 0.05),但在悬浮细胞群中CD11c+计数无显著差异。培养法黏附细胞群和悬浮细胞群中CD11c+含量均显著升高,但试剂盒法仅悬浮细胞群中CD11c+含量较高。另一方面,使用这两种方法,未成熟DC表达中等水平的MHC II类分子,以及低水平的CD40和CD86。我们的研究结果表明,广泛使用的培养方法在贴壁和悬浮细胞群体的BMDCs产量、活力和纯度方面都有最好的结果,而试剂盒法在悬浮细胞群体中效果良好。
{"title":"Optimization of <i>Ex Vivo</i> Murine Bone Marrow Derived Immature Dendritic Cells: A Comparative Analysis of Flask Culture Method and Mouse CD11c Positive Selection Kit Method.","authors":"Rahul Ashok Gosavi,&nbsp;Sukeshani Salwe,&nbsp;Sandeepan Mukherjee,&nbsp;Ritwik Dahake,&nbsp;Sweta Kothari,&nbsp;Vainav Patel,&nbsp;Abhay Chowdhary,&nbsp;Ranjana A Deshmukh","doi":"10.1155/2018/3495086","DOIUrl":"https://doi.org/10.1155/2018/3495086","url":null,"abstract":"<p><p>12-14 days of culturing of bone marrow (BM) cells containing various growth factors is widely used method for generating dendritic cells (DCs) from suspended cell population. Here we compared flask culture method and commercially available CD11c Positive Selection kit method. Immature BMDCs' purity of adherent as well as suspended cell population was generated in the decreasing concentration of recombinant-murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) in nontreated tissue culture flasks. The expression of CD11c, MHCII, CD40, and CD86 was measured by flow cytometry. We found significant difference (<i>P</i> < 0.05) between the two methods in the adherent cells population but no significant difference was observed between the suspended cell populations with respect to CD11c+ count. However, CD11c+ was significantly higher in both adhered and suspended cell population by culture method but kit method gave more CD11c+ from suspended cells population only. On the other hand, using both methods, immature DC expressed moderate level of MHC class II molecules as well as low levels of CD40 and CD86. Our findings suggest that widely used culture method gives the best results in terms of yield, viability, and purity of BMDCs from both adherent and suspended cell population whereas kit method works well for suspended cell population.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/3495086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36034296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
A Reliable and Reproducible Model for Assessing the Effect of Different Concentrations of α-Solanine on Rat Bone Marrow Mesenchymal Stem Cells. 不同浓度α-龙葵碱对大鼠骨髓间充质干细胞影响的可靠、可重复模型
Pub Date : 2017-01-01 Epub Date: 2017-10-22 DOI: 10.1155/2017/2170306
Adriana Ordóñez-Vásquez, Lorenza Jaramillo-Gómez, Camilo Duran-Correa, Erandi Escamilla-García, Myriam Angélica De la Garza-Ramos, Fernando Suárez-Obando

Αlpha-solanine (α-solanine) is a glycoalkaloid present in potato (Solanum tuberosum). It has been of particular interest because of its toxicity and potential teratogenic effects that include abnormalities of the central nervous system, such as exencephaly, encephalocele, and anophthalmia. Various types of cell culture have been used as experimental models to determine the effect of α-solanine on cell physiology. The morphological changes in the mesenchymal stem cell upon exposure to α-solanine have not been established. This study aimed to describe a reliable and reproducible model for assessing the structural changes induced by exposure of mouse bone marrow mesenchymal stem cells (MSCs) to different concentrations of α-solanine for 24 h. The results demonstrate that nonlethal concentrations of α-solanine (2-6 μM) changed the morphology of the cells, including an increase in the number of nucleoli, suggesting elevated protein synthesis, and the formation of spicules. In addition, treatment with α-solanine reduced the number of adherent cells and the formation of colonies in culture. Immunophenotypic characterization and staining of MSCs are proposed as a reproducible method that allows description of cells exposed to the glycoalkaloid, α-solanine.

Αlpha-solanine (α-茄碱)是马铃薯(Solanum tuberosum)中的一种糖生物碱。由于其毒性和潜在的致畸作用,包括中枢神经系统异常,如脑畸形、脑膨出和眼失。以不同类型的细胞培养为实验模型,研究α-龙葵碱对细胞生理的影响。α-龙葵碱对间充质干细胞的影响尚不清楚。本研究旨在建立一种可靠、可重复的模型,用于评估小鼠骨髓间充质干细胞(MSCs)暴露于不同浓度α-龙葵碱24小时后的结构变化。结果表明,非致死浓度α-龙葵碱(2-6 μM)改变了细胞形态,包括核仁数量增加,表明蛋白质合成增加,针状体形成。此外,α-龙葵碱处理减少了培养中贴壁细胞数量和菌落形成。MSCs的免疫表型表征和染色被提议作为一种可重复的方法,允许描述暴露于糖生物碱α-龙葵碱的细胞。
{"title":"A Reliable and Reproducible Model for Assessing the Effect of Different Concentrations of <i>α</i>-Solanine on Rat Bone Marrow Mesenchymal Stem Cells.","authors":"Adriana Ordóñez-Vásquez,&nbsp;Lorenza Jaramillo-Gómez,&nbsp;Camilo Duran-Correa,&nbsp;Erandi Escamilla-García,&nbsp;Myriam Angélica De la Garza-Ramos,&nbsp;Fernando Suárez-Obando","doi":"10.1155/2017/2170306","DOIUrl":"https://doi.org/10.1155/2017/2170306","url":null,"abstract":"<p><p>Αlpha-solanine (<i>α</i>-solanine) is a glycoalkaloid present in potato <i>(Solanum tuberosum)</i>. It has been of particular interest because of its toxicity and potential teratogenic effects that include abnormalities of the central nervous system, such as exencephaly, encephalocele, and anophthalmia. Various types of cell culture have been used as experimental models to determine the effect of <i>α</i>-solanine on cell physiology. The morphological changes in the mesenchymal stem cell upon exposure to <i>α</i>-solanine have not been established. This study aimed to describe a reliable and reproducible model for assessing the structural changes induced by exposure of mouse bone marrow mesenchymal stem cells (MSCs) to different concentrations of <i>α</i>-solanine for 24 h. The results demonstrate that nonlethal concentrations of <i>α</i>-solanine (2-6 <i>μ</i>M) changed the morphology of the cells, including an increase in the number of nucleoli, suggesting elevated protein synthesis, and the formation of spicules. In addition, treatment with <i>α</i>-solanine reduced the number of adherent cells and the formation of colonies in culture. Immunophenotypic characterization and staining of MSCs are proposed as a reproducible method that allows description of cells exposed to the glycoalkaloid, <i>α</i>-solanine.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2170306","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35218925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Feasibility and Efficacy of Autologous Bone Marrow Aspirate Transplantation Combined with Human Parathyroid Hormone 1-34 Administration to Treat Osteonecrosis in a Rabbit Model. 自体骨髓抽吸联合人甲状旁腺激素1-34治疗家兔骨坏死模型的可行性及疗效。
Pub Date : 2017-01-01 Epub Date: 2017-03-13 DOI: 10.1155/2017/2484689
Takeshi Makihara, Tomokazu Yoshioka, Hisashi Sugaya, Katsuya Aoto, Hiroshi Wada, Kenta Uemura, Kenta Tanaka, Hiroshi Akaogi, Masashi Yamazaki, Hajime Mishima

No studies have examined the transplantation of a bone marrow aspirate (BMA) containing mesenchymal stem cells (MSCs) combined with human parathyroid hormone 1-34 (hPTH1-34) administration. Therefore, we evaluated the feasibility and efficacy of autologous BMA transplantation combined with hPHT1-34 administration in a bone necrosis model. The metatarsal bones of rabbits were necrotized using liquid nitrogen, and the rabbits received a BMA transplantation or saline injection followed by hPTH1-34 (30 μg/kg) or saline administration three times per week (n = 3-4 per group). The rabbits were euthanized at 12 weeks after the initiation of treatment. No systemic adverse effects or local neoplastic lesions were observed. Importantly, the rabbits in the BMA transplantation plus hPTH1-34 group showed the highest bone volumes and histological scores of new bone. These data confirmed the feasibility of BMA transplantation combined with hPTH1-34, at least during the experimental period. The observed efficacy may be explained by a synergistic effect from the stimulation of MSC differentiation to osteoblasts with hPTH1-34-mediated suppression of apoptosis in osteoblasts. These results indicate the promising potential for BMA transplantation combined with hPTH1-34 administration in bone necrosis treatment. Longer term experiments are needed to confirm the safety of this therapeutic strategy.

目前还没有研究检测含有间充质干细胞(MSCs)的骨髓抽吸液(BMA)联合人甲状旁腺激素1-34 (hPTH1-34)的移植。因此,我们在骨坏死模型中评估自体BMA移植联合hPHT1-34给药的可行性和疗效。采用液氮对兔跖骨进行坏死处理,术后给予BMA移植或生理盐水注射,再给予hPTH1-34 (30 μg/kg)或生理盐水,每周3次(每组n = 3-4次)。治疗开始后12周对家兔实施安乐死。没有观察到全身不良反应或局部肿瘤病变。重要的是,BMA + hPTH1-34组的兔骨体积和新骨组织学评分最高。这些数据至少在实验期间证实了BMA联合hPTH1-34移植的可行性。观察到的效果可能是通过刺激MSC分化成骨细胞与hpth1 -34介导的成骨细胞凋亡抑制的协同作用来解释的。这些结果表明BMA移植联合hPTH1-34治疗骨坏死有很大的潜力。需要更长期的实验来证实这种治疗策略的安全性。
{"title":"Feasibility and Efficacy of Autologous Bone Marrow Aspirate Transplantation Combined with Human Parathyroid Hormone 1-34 Administration to Treat Osteonecrosis in a Rabbit Model.","authors":"Takeshi Makihara,&nbsp;Tomokazu Yoshioka,&nbsp;Hisashi Sugaya,&nbsp;Katsuya Aoto,&nbsp;Hiroshi Wada,&nbsp;Kenta Uemura,&nbsp;Kenta Tanaka,&nbsp;Hiroshi Akaogi,&nbsp;Masashi Yamazaki,&nbsp;Hajime Mishima","doi":"10.1155/2017/2484689","DOIUrl":"https://doi.org/10.1155/2017/2484689","url":null,"abstract":"<p><p>No studies have examined the transplantation of a bone marrow aspirate (BMA) containing mesenchymal stem cells (MSCs) combined with human parathyroid hormone 1-34 (hPTH1-34) administration. Therefore, we evaluated the feasibility and efficacy of autologous BMA transplantation combined with hPHT1-34 administration in a bone necrosis model. The metatarsal bones of rabbits were necrotized using liquid nitrogen, and the rabbits received a BMA transplantation or saline injection followed by hPTH1-34 (30 <i>μ</i>g/kg) or saline administration three times per week (<i>n</i> = 3-4 per group). The rabbits were euthanized at 12 weeks after the initiation of treatment. No systemic adverse effects or local neoplastic lesions were observed. Importantly, the rabbits in the BMA transplantation plus hPTH1-34 group showed the highest bone volumes and histological scores of new bone. These data confirmed the feasibility of BMA transplantation combined with hPTH1-34, at least during the experimental period. The observed efficacy may be explained by a synergistic effect from the stimulation of MSC differentiation to osteoblasts with hPTH1-34-mediated suppression of apoptosis in osteoblasts. These results indicate the promising potential for BMA transplantation combined with hPTH1-34 administration in bone necrosis treatment. Longer term experiments are needed to confirm the safety of this therapeutic strategy.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2484689","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34893805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare 使用SEER-Medicare治疗老年多发性骨髓瘤患者自体干细胞移植合并症的成本影响
Pub Date : 2016-10-18 DOI: 10.1155/2016/3645623
G. Shah, Aaron N. Winn, P. Lin, A. Klein, K. Sprague, Hedy P. Smith, R. Buchsbaum, Joshua T. Cohen, K. Miller, R. Comenzo, S. Parsons
Comorbidity is more common in older patients and can increase the cost of care by increasing toxicity. Using the SEER-Medicare database from 2000 to 2007, we examined the costs and life-year benefit of Auto-HSCT for MM patients over the age of 65 by evaluating the difference over time relative to comorbidity burden. One hundred ten patients had an Auto-HSCT in the early time period (2000–2003) and 160 in the late time period (2004–2007). Patients were divided by a Charlson Comorbidity Index (CCI) of 0 or greater than 1 (CCI1+). Median overall survival was 53.5 months for the late time period patients compared to 40.3 months for the early time period patients (p = 0.031). Median costs for CCI0 versus CCI1+ in the early period were, respectively, $70,900 versus $72,000 (100 d); $86,100 versus $98,300 (1 yr); and $139,200 versus $195,300 (3 yrs). Median costs for late period were, respectively, $58,400 versus $60,400 (100 d); $86,300 versus $77,700 (1 yr); and $124,400 versus $110,900 (3 yrs). Comorbidity had a significant impact on survival and cost among early time period patients but not among late time period patients. Therefore, older patients with some comorbidities can be considered for Auto-HSCT depending on clinical circumstances.
合并症在老年患者中更为常见,并且可以通过增加毒性来增加护理成本。使用2000年至2007年的SEER-Medicare数据库,我们通过评估相对于共病负担的时间差异,检查了65岁以上MM患者Auto-HSCT的成本和生命年收益。110例患者在早期(2000-2003年)进行了自体造血干细胞移植,160例在晚期(2004-2007年)进行了自体造血干细胞移植。患者按Charlson合并症指数(CCI)为0或大于1 (CCI1+)进行分组。晚期患者的中位总生存期为53.5个月,而早期患者为40.3个月(p = 0.031)。早期CCI0和CCI1+的中位成本分别为70,900美元和72,000美元(100 d);86,100美元对98,300美元(1年);139,200美元对195,300美元(3年)。后期的中位数成本分别为58,400美元和60,400美元(100 d);86,300美元对77,700美元(1年);124,400美元对110,900美元(3年)。合并症对早期患者的生存和成本有显著影响,但对晚期患者无显著影响。因此,有一些合并症的老年患者可以根据临床情况考虑进行Auto-HSCT。
{"title":"Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare","authors":"G. Shah, Aaron N. Winn, P. Lin, A. Klein, K. Sprague, Hedy P. Smith, R. Buchsbaum, Joshua T. Cohen, K. Miller, R. Comenzo, S. Parsons","doi":"10.1155/2016/3645623","DOIUrl":"https://doi.org/10.1155/2016/3645623","url":null,"abstract":"Comorbidity is more common in older patients and can increase the cost of care by increasing toxicity. Using the SEER-Medicare database from 2000 to 2007, we examined the costs and life-year benefit of Auto-HSCT for MM patients over the age of 65 by evaluating the difference over time relative to comorbidity burden. One hundred ten patients had an Auto-HSCT in the early time period (2000–2003) and 160 in the late time period (2004–2007). Patients were divided by a Charlson Comorbidity Index (CCI) of 0 or greater than 1 (CCI1+). Median overall survival was 53.5 months for the late time period patients compared to 40.3 months for the early time period patients (p = 0.031). Median costs for CCI0 versus CCI1+ in the early period were, respectively, $70,900 versus $72,000 (100 d); $86,100 versus $98,300 (1 yr); and $139,200 versus $195,300 (3 yrs). Median costs for late period were, respectively, $58,400 versus $60,400 (100 d); $86,300 versus $77,700 (1 yr); and $124,400 versus $110,900 (3 yrs). Comorbidity had a significant impact on survival and cost among early time period patients but not among late time period patients. Therefore, older patients with some comorbidities can be considered for Auto-HSCT depending on clinical circumstances.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77642875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies 微血管密度和血管内皮生长因子在血液恶性肿瘤血管生成中的作用
Pub Date : 2016-02-22 DOI: 10.1155/2016/5043483
R. Chand, H. Chandra, S. Chandra, S. Verma
Angiogenesis plays an important role in progression of tumor with vascular endothelial growth factor (VEGF) being key proangiogenic factor. It was intended to study angiogenesis in different hematological malignancies by quantifying expression of VEGF and MVD in bone marrow biopsy along with serum VEGF levels and observing its change following therapy. The study included 50 cases of hematological malignancies which were followed for one month after initial therapy along with 30 controls. All of them were subjected to immunostaining by anti-VEGF and factor VIII antibodies on bone marrow biopsy along with the measurement of serum VEGF levels. Significantly higher pretreatment VEGF scores, serum VEGF levels, and MVD were observed in cases as compared to controls (p < 0.05). The highest VEGF score and serum VEGF were observed in chronic myeloid leukemia and maximum MVD in Non-Hodgkin's Lymphoma. Significant decrease in serum VEGF levels after treatment was observed in all hematological malignancies except for AML. To conclude angiogenesis plays an important role in pathogenesis of all the hematological malignancies as reflected by increased VEGF expression and MVD in bone marrow biopsy along with increased serum VEGF level. The decrease in serum VEGF level after therapy further supports this view and also lays the importance of anti angiogenic therapy.
血管生成在肿瘤的发展过程中起着重要作用,而血管内皮生长因子(VEGF)是促血管生成的关键因子。通过定量骨髓活检组织中VEGF和MVD的表达及血清VEGF水平,观察其治疗后的变化,研究不同血液恶性肿瘤的血管生成。该研究包括50例血液系统恶性肿瘤患者,在初始治疗后随访一个月,并与30例对照。骨髓活检行抗VEGF和因子VIII抗体免疫染色,测定血清VEGF水平。治疗前VEGF评分、血清VEGF水平、MVD均显著高于对照组(p < 0.05)。VEGF评分和血清VEGF以慢性髓系白血病最高,MVD以非霍奇金淋巴瘤最高。除AML外,所有血液系统恶性肿瘤治疗后血清VEGF水平均显著下降。结论血管生成在所有血液系统恶性肿瘤的发病机制中起重要作用,骨髓活检中VEGF表达和MVD升高,血清VEGF水平升高。治疗后血清VEGF水平的下降进一步支持了这一观点,也说明了抗血管生成治疗的重要性。
{"title":"Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies","authors":"R. Chand, H. Chandra, S. Chandra, S. Verma","doi":"10.1155/2016/5043483","DOIUrl":"https://doi.org/10.1155/2016/5043483","url":null,"abstract":"Angiogenesis plays an important role in progression of tumor with vascular endothelial growth factor (VEGF) being key proangiogenic factor. It was intended to study angiogenesis in different hematological malignancies by quantifying expression of VEGF and MVD in bone marrow biopsy along with serum VEGF levels and observing its change following therapy. The study included 50 cases of hematological malignancies which were followed for one month after initial therapy along with 30 controls. All of them were subjected to immunostaining by anti-VEGF and factor VIII antibodies on bone marrow biopsy along with the measurement of serum VEGF levels. Significantly higher pretreatment VEGF scores, serum VEGF levels, and MVD were observed in cases as compared to controls (p < 0.05). The highest VEGF score and serum VEGF were observed in chronic myeloid leukemia and maximum MVD in Non-Hodgkin's Lymphoma. Significant decrease in serum VEGF levels after treatment was observed in all hematological malignancies except for AML. To conclude angiogenesis plays an important role in pathogenesis of all the hematological malignancies as reflected by increased VEGF expression and MVD in bone marrow biopsy along with increased serum VEGF level. The decrease in serum VEGF level after therapy further supports this view and also lays the importance of anti angiogenic therapy.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79292143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 30
A Simplified Method for the Aspiration of Bone Marrow from Patients Undergoing Hip and Knee Joint Replacement for Isolating Mesenchymal Stem Cells and In Vitro Chondrogenesis 髋关节和膝关节置换术患者骨髓分离间充质干细胞和体外软骨形成的简化方法
Pub Date : 2016-02-11 DOI: 10.1155/2016/3152065
S. Juneja, S. Viswanathan, M. Ganguly, C. Veillette
The procedure for aspiration of bone marrow from the femur of patients undergoing total knee arthroplasty (TKA) or total hip arthroplasty (THA) may vary from an OR (operating room) to OR based on the surgeon's skill and may lead to varied extent of clotting of the marrow and this, in turn, presents difficulty in the isolation of mesenchymal stem cells (MSCs) from such clotted bone marrow. We present a simple detailed protocol for aspirating bone marrow from such patients, isolation, and characterization of MSCs from the aspirated bone marrow specimens and show that the bone marrow presented no clotting or exhibited minimal clotting. This represents an economical source and convenient source of MSCs from bone marrow for use in regenerative medicine. Also, we presented the detailed protocol and showed that the MSCs derived from such bone marrow specimens exhibited MSCs characteristics and generated micromass cartilages, the recipe for regenerative medicine for osteoarthritis. The protocols we presented can be used as standard operating procedures (SOPs) by researchers and clinicians.
接受全膝关节置换术(TKA)或全髋关节置换术(THA)的患者,从股骨中抽取骨髓的程序可能因手术室(手术室)的不同而不同,这取决于外科医生的技术,可能导致不同程度的骨髓凝血,这反过来又给从这种凝血的骨髓中分离间充质干细胞(MSCs)带来困难。我们提出了一个简单详细的方案,用于从这些患者中抽取骨髓,从抽取的骨髓标本中分离和表征MSCs,并表明骨髓没有凝血或表现出最小的凝血。这是一种经济、方便的骨髓间充质干细胞来源,可用于再生医学。此外,我们提出了详细的方案,并表明从这些骨髓标本中提取的间充质干细胞具有间充质干细胞的特征,并产生微团软骨,这是骨关节炎再生医学的配方。我们提出的方案可以作为研究人员和临床医生的标准操作程序(sop)。
{"title":"A Simplified Method for the Aspiration of Bone Marrow from Patients Undergoing Hip and Knee Joint Replacement for Isolating Mesenchymal Stem Cells and In Vitro Chondrogenesis","authors":"S. Juneja, S. Viswanathan, M. Ganguly, C. Veillette","doi":"10.1155/2016/3152065","DOIUrl":"https://doi.org/10.1155/2016/3152065","url":null,"abstract":"The procedure for aspiration of bone marrow from the femur of patients undergoing total knee arthroplasty (TKA) or total hip arthroplasty (THA) may vary from an OR (operating room) to OR based on the surgeon's skill and may lead to varied extent of clotting of the marrow and this, in turn, presents difficulty in the isolation of mesenchymal stem cells (MSCs) from such clotted bone marrow. We present a simple detailed protocol for aspirating bone marrow from such patients, isolation, and characterization of MSCs from the aspirated bone marrow specimens and show that the bone marrow presented no clotting or exhibited minimal clotting. This represents an economical source and convenient source of MSCs from bone marrow for use in regenerative medicine. Also, we presented the detailed protocol and showed that the MSCs derived from such bone marrow specimens exhibited MSCs characteristics and generated micromass cartilages, the recipe for regenerative medicine for osteoarthritis. The protocols we presented can be used as standard operating procedures (SOPs) by researchers and clinicians.","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84113807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Awareness, Knowledge, and Acceptance of Haematopoietic Stem Cell Transplantation for Sickle Cell Anaemia in Nigeria. 尼日利亚对造血干细胞移植治疗镰状细胞性贫血的认识、知识和接受程度。
Pub Date : 2016-01-01 Epub Date: 2016-09-27 DOI: 10.1155/2016/7062630
Adewumi Adediran, Modu Baba Kagu, Tamunomieibi Wakama, Aliyu Ahmadu Babadoko, Dapus Obadiah Damulak, Sunday Ocheni, Marcus Inyama Asuquo

Background. Sickle cell anaemia (SCA) is an inherited condition whose clinical manifestations arise from the tendency of haemoglobin to polymerize and deform red blood cells into characteristic sickle shape. Allogeneic bone marrow transplantation offers a cure. The aim of this study was to determine the level of awareness, knowledge, and acceptance of this beneficial procedure in Nigeria. Materials and Methods. This multicentre cross-sectional study was conducted in 7 tertiary hospitals in Nigeria in 2015. Approval was obtained from each institution's research and ethics committee. A pretested structured questionnaire was administered to respondents aged 18 years and above and to the parents or guardians of those below 18 years of age. Results. There were 265 respondents comprising 120 males and 145 females. One hundred and seventy-one (64.5%) respondents were aware of BMT for the treatment of SCA. About 67.8% (116 of 171) of those who were aware believed SCA can be cured with BMT (p = 0.001) and 49.7% (85 of 171) of the respondents accepted BMT (p = 0.001). Conclusion. Awareness of BMT in Nigeria is low when compared with reports from developed countries. The knowledge is poor and acceptance is low. With adequate information, improved education, and psychological support, more Nigerians will embrace BMT.

背景。镰状细胞性贫血(SCA)是一种遗传性疾病,其临床表现是由于血红蛋白容易聚合,使红细胞变形为镰状。异体骨髓移植可以治愈这种疾病。本研究旨在确定尼日利亚对这一有益手术的认识、了解和接受程度。材料和方法。这项多中心横断面研究于 2015 年在尼日利亚的 7 家三级医院进行。研究获得了各机构研究和伦理委员会的批准。对 18 岁及以上的受访者和 18 岁以下受访者的父母或监护人进行了预先测试的结构式问卷调查。结果。共有 265 名受访者,其中男性 120 人,女性 145 人。171名受访者(64.5%)知道 BMT 可用于治疗 SCA。约 67.8%(171 人中的 116 人)的受访者认为 BMT 可以治愈 SCA(p = 0.001),49.7%(171 人中的 85 人)的受访者接受 BMT(p = 0.001)。结论。与发达国家的报告相比,尼日利亚对 BMT 的认知度较低。知识水平低,接受度也低。如果有足够的信息、更好的教育和心理支持,将会有更多的尼日利亚人接受 BMT。
{"title":"Awareness, Knowledge, and Acceptance of Haematopoietic Stem Cell Transplantation for Sickle Cell Anaemia in Nigeria.","authors":"Adewumi Adediran, Modu Baba Kagu, Tamunomieibi Wakama, Aliyu Ahmadu Babadoko, Dapus Obadiah Damulak, Sunday Ocheni, Marcus Inyama Asuquo","doi":"10.1155/2016/7062630","DOIUrl":"10.1155/2016/7062630","url":null,"abstract":"<p><p><i>Background.</i> Sickle cell anaemia (SCA) is an inherited condition whose clinical manifestations arise from the tendency of haemoglobin to polymerize and deform red blood cells into characteristic sickle shape. Allogeneic bone marrow transplantation offers a cure. The aim of this study was to determine the level of awareness, knowledge, and acceptance of this beneficial procedure in Nigeria. <i>Materials and Methods.</i> This multicentre cross-sectional study was conducted in 7 tertiary hospitals in Nigeria in 2015. Approval was obtained from each institution's research and ethics committee. A pretested structured questionnaire was administered to respondents aged 18 years and above and to the parents or guardians of those below 18 years of age. <i>Results.</i> There were 265 respondents comprising 120 males and 145 females. One hundred and seventy-one (64.5%) respondents were aware of BMT for the treatment of SCA. About 67.8% (116 of 171) of those who were aware believed SCA can be cured with BMT (<i>p</i> = 0.001) and 49.7% (85 of 171) of the respondents accepted BMT (<i>p</i> = 0.001). <i>Conclusion.</i> Awareness of BMT in Nigeria is low when compared with reports from developed countries. The knowledge is poor and acceptance is low. With adequate information, improved education, and psychological support, more Nigerians will embrace BMT.</p>","PeriodicalId":9220,"journal":{"name":"Bone Marrow Research","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83382395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bone Marrow Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1